Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$13.75
$13.74
$4.41
$13.80
$477.47M0.89950,664 shsN/A
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$8.00
-1.1%
$7.97
$6.10
$28.67
$560.26M1.41397,467 shs214,585 shs
Kamada Ltd. stock logo
KMDA
Kamada
$7.75
-3.4%
$7.15
$5.08
$9.16
$461.19M0.9696,112 shs59,663 shs
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$1.16
$0.98
$4.95
$69.47M2.34396,682 shs296,500 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.01
+12.2%
$0.03
$0.00
$6.93
$271K1.318.06 million shs130,272 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-1.11%+7.74%-8.68%+19.40%-61.92%
Kamada Ltd. stock logo
KMDA
Kamada
-3.37%-0.08%+11.51%+27.68%+31.36%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
+12.22%-59.76%-57.38%-57.92%-99.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
3.7403 of 5 stars
4.42.00.00.02.34.20.6
Kamada Ltd. stock logo
KMDA
Kamada
3.9456 of 5 stars
3.33.00.00.02.91.73.1
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
4.1644 of 5 stars
3.14.00.04.31.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00
N/AN/AN/A
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
2.70
Moderate Buy$25.00212.50% Upside
Kamada Ltd. stock logo
KMDA
Kamada
2.67
Moderate Buy$13.0067.74% Upside
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.20
Hold$3.3332,903.30% Upside

Current Analyst Ratings Breakdown

Latest SYRS, KMDA, OSMT, AMAG, and BCYC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/5/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/1/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$327.75M1.46N/AN/A$7.37 per share1.87
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$35.28M15.70N/AN/A$11.48 per share0.70
Kamada Ltd. stock logo
KMDA
Kamada
$160.95M2.77$0.48 per share16.31$4.51 per share1.72
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$177.88M0.00N/A1.00$1.50 per share0.00
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.70N/AN/A$0.79 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/A
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)
Kamada Ltd. stock logo
KMDA
Kamada
$14.46M$0.2926.7224.220.979.60%6.31%4.43%8/13/2025 (Estimated)
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)

Latest SYRS, KMDA, OSMT, AMAG, and BCYC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.95N/AN/AN/A$9.43 millionN/A
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/1/2025Q1 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/A
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
1.13
1.75
1.45
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/A
14.86
14.86
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.30
1.93
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/A
0.43
0.42
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/A
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
86.15%
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
46.18%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
44034.73 millionN/AOptionable
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
24069.25 million53.40 millionOptionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.51 million36.75 millionOptionable
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
30262.59 million59.32 millionNot Optionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionOptionable

Recent News About These Companies

Syros Pharmaceuticals trading resumes
Syros Pharmaceuticals Plans to Wind Down Operations
SYRS’s Latest Surge: What’s Behind the Spike?

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMAG Pharmaceuticals stock logo

AMAG Pharmaceuticals NASDAQ:AMAG

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Bicycle Therapeutics stock logo

Bicycle Therapeutics NASDAQ:BCYC

$8.00 -0.09 (-1.11%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$7.50 -0.51 (-6.31%)
As of 07/11/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Kamada stock logo

Kamada NASDAQ:KMDA

$7.75 -0.27 (-3.37%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$7.76 +0.01 (+0.13%)
As of 07/11/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Osmotica Pharmaceuticals stock logo

Osmotica Pharmaceuticals NASDAQ:OSMT

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.01 +0.00 (+12.22%)
As of 07/11/2025 02:56 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.